I have been a little surprised that no question came up yesterday or in previous presentation by CFO about whether MNTA was developing their Humira biosimilar to be interchangable and Craig simply referred to it as a high quality biosimilar and interchangable status was never mentioned. Is there a reason they would not talk about that? Thanks
Market Data 
Markets 
AI
